Promising Phase 2 Trial Results For Patients With Myelodysplastic Syndrome and AML

1 Views

07/04/23

Jennifer Elliott, PhD, Global Project Leader at Takeda Oncology discusses the results of the phase 2 P2001 study presented at ASCO 2020. This clinical trial’s primary goal was to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine in patients with high-risk or chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML).

For more information about myelodysplastic syndromes, CMML, AML, and other rare hematologic disorders, visit https://checkrare.com/diseases..../hematologic-disorde